公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2006 | Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer | Shiah H.-S.; ANN-LII CHENG ; CHIUN HSU ; CHIH-HUNG HSU ; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 6 | 5 | |
2017 | A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma | Yau T.C.C.; Lencioni R.; Sukeepaisarnjaroen W.; Chao Y.; Yen C.-J.; Lausoontornsiri W.; PEI-JER CHEN ; Sanpajit T.; Camp A.; Cox D.S.; Gagnon R.C.; Liu Y.; Raffensperger K.E.; Kulkarni D.A.; Kallender H.; Ottesen L.H.; Poon R.T.P.; Bottaro D.P. | Clinical Cancer Research | 45 | 38 | |
2018 | A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma | Yen C.-J.; Kim T.-Y.; Feng Y.-H.; Chao Y.; Lin D.-Y.; Ryoo B.-Y.; Huang D.C.-L.; Schnell D.; Hocke J.; Loemb? A.-B.; ANN-LII CHENG | Liver Cancer | 19 | 22 | |
2020 | Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors | Desai J.; Deva S.; Lee J.S.; CHIA-CHI LIN ; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. | Journal for ImmunoTherapy of Cancer | 79 | 73 | |
2011 | A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan | Chen J.-S.; Chao Y.; Hsieh R.-K.; ANN-LII CHENG ; Chen P.-M.; Chiou T.-J.; Chao T.-Y.; KUN-HUEI YEH ; Chen L.-T.; Whang-Peng J. | Cancer Chemotherapy and Pharmacology | 6 | 5 | |
2014 | Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer | Ying-Chun Shen ; Li C.-P.; Yen C.-J.; CHIUN HSU ; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH ; ANN-LII CHENG | Oncology (Switzerland) | 15 | 12 | |
2004 | Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer | Chao Y.; KUN-HUEI YEH ; Chang C.J.; Chen L.T.; Chao T.Y.; Wu M.F.; Chang C.S.; Chang J.Y.; Chung C.Y.; Kao W.Y.; Hsieh R.K.; ANN-LII CHENG | British Journal of Cancer | 72 | 63 | |
2021 | Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma | Hung Y.-P.; YU-YUN SHAO ; Lee J.-M.; CHIUN HSU ; CHIH-HUNG HSU ; Yang M.-H.; Chao Y. | Journal of the Chinese Medical Association | 10 | 9 | |
2018 | Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials | Yen C.-J.; Muro K.; Kim T.-W.; Kudo M.; JIN-YUAN SHIH ; Lee K.-W.; Chao Y.; Kim S.-W.; Yamazaki K.; Sohn J.; Cheng R.; Zhang Y.; Binder P.; Mi G.; Orlando M.; Chung H.C. | Journal of Global Oncology | 9 | 0 | |
2010 | A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients | Yang T.-S.; Lu S.-N.; Chao Y.; Sheen I.-S.; Lin C.-C.; Wang T.-E.; Chen S.-C.; Wang J.-H.; Liao L.-Y.; Thomson J.A.; Wang-Peng J.; PEI-JER CHEN ; Chen L.-T. | British Journal of Cancer | 134 | 124 | |
2016 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma | ANN-LII CHENG ; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. | Hepatology | 71 | 68 | |
2014 | Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel | ANN-LII CHENG ; Amarapurkar D.; Chao Y.; PEI-JER CHEN ; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. | Liver International | 74 | 69 | |
2012 | STI571 reduces TRAIL-induced apoptosis in colon cancer cells: C-Abl activation by the death receptor leads to stress kinase-dependent cell death | Huang D.-Y.; Chao Y.; Tai M.-H.; Yu Y.-H.; WAN-WAN LIN | Journal of Biomedical Science | 18 | 17 | |
2021 | Survival outcomes of management in metastatic gastric adenocarcinoma patients | Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; CHUN-JU CHIANG ; Li A.F.-Y.; HSIU-PO WANG ; Wang T.-E.; Bai L.-Y.; MING-SHIANG WU ; Chen L.-T.; Liu T.-W.; Yang Y.-H. | Scientific Reports | 20 | 13 | |
2022 | Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma | Hsu F.-T.; Tsai C.L.; Chiang I.-T.; KENG-HSUEH LAN ; Yueh P.-F.; Liang W.-Y.; Lin C.-S.; Chao Y.; Lan K.-L. | Journal of Cellular and Molecular Medicine | 3 | 1 | |
2021 | The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma | Hung Y.-P.; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; Lee J.-M.; Yang M.-H.; Chao Y. | Journal of the Formosan Medical Association | 4 | 4 | |
2012 | Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study | CHIUN HSU ; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; CHIH-WEI YU ; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; ANN-LII CHENG | Journal of Hepatology | 79 | 74 | |